IMVT - Company ID 0001764013
Immunovant, Inc. trades as IMVT and has a market capitalization of $8.40 B, making it the #1064 largest US-listed company by market value. This page tracks Immunovant, Inc. through 611 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Annual report | 10-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-20 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-01 |
| Insider trade | 4 | 2026-05-01 |
| Insider trade | 4 | 2026-04-24 |
The largest companies sharing Immunovant, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Immunovant, Inc. (IMVT) has a market capitalization of $8.40 B as of 2026-07-09, ranking #1064 among US-listed companies.
In its latest fiscal year Immunovant, Inc. reported a net loss of $505.61M.